Navigation Links
BioMarin to Present at the Wedbush Life Sciences Conference
Date:8/9/2011

NOVATO, Calif., Aug. 9, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Wedbush Life Sciences Conference in New York on Tuesday, August 16, 2011 at 10:00 a.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Announces Second Quarter 2011 Financial Results
2. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
3. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
4. BioMarin to Present at the William Blair Growth Stock Conference
5. BioMarin to Present at the Jefferies Global Healthcare Conference
6. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
7. BioMarin Announces First Quarter 2011 Financial Results
8. BioMarin to Present at the Deutsche Bank Healthcare Conference
9. BioMarin to Present at the Barclays Global Healthcare Conference
10. BioMarin to Present at the Cowen Health Care Conference
11. BioMarin to Present at the Citi Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Eisai Inc. announced today new analyses and ... of the American Epilepsy Society (AES). ... adjunctive therapy for the treatment of partial onset seizures ... generalized tonic-clonic seizures (PGTC) in patients with epilepsy who ... Important Safety Information for FYCOMPA, including Boxed WARNING for ...
(Date:12/5/2016)... , Dec 5, 2016 Research and ... and Pregnancy Rapid Test Market Size, Share, Development, Growth and Demand ... ... The global female fertility and pregnancy rapid test market is ... global Female fertility and pregnancy rapid test market is witnessing high ...
(Date:12/5/2016)... AVIV, Israel , December 5, 2016 ... to identifying, in-licensing and developing promising therapeutic candidates, presents positive ... for BL-8040, the Company,s leading oncology platform at the ongoing ... in San Diego, California . ... , , ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... 06, 2016 , ... For many years, Andrew G. Zubinas has ... The beauty of the Lithuanian language and its poetry inspired him in ... Zubinas lyrically explores all aspects of a living, breathing forest where nothing ever stays ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy ... through tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on the ... 26 people will be diagnosed with epilepsy within their lifetime. With such a ...
(Date:12/5/2016)... Reading, PA (PRWEB) , ... December 05, 2016 , ... ... partner in the United States and Canada for distribution of their natural fruits ... Hansen colors line is an exciting addition to our Life Sciences product portfolio,” ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Partners ("GPP") portfolio company, today announced it has acquired the assets of ... was previously a subsidiary of Chiltern International and focuses on clinical trial ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... The new ... the individual looking to buy neoprene knee sleeves for lifting and any ... design focuses heavily on two main aspects to provide a higher quality knee sleeve ...
Breaking Medicine News(10 mins):